Lunit Inc.
8
0
1
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 8 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
Digital Breast Tomosynthesis for the Dutch National Breast Cancer Screening Program
Role: collaborator
Multi-Reader, Multi-Case, Cross-Over, Retrospective Study to Evaluate Effectiveness of Lunit INSIGHT DBT
Role: lead
Real World Evaluation of Lunit INSIGHT MMG Technology
Role: lead
A Study to Assess the Impact of an Artificial Intelligence (AI) System on Chest X-ray Reporting
Role: collaborator
Artificial Intelligence in Large-scale Breast Cancer Screening
Role: collaborator
Study to Evaluate the Effectiveness of the Device in Detection of Abnormal Findings on X-ray
Role: lead
Study to Evaluate the Effectiveness of the Device in Detection of Abnormal Findings on Chest X-ray
Role: lead
Study to Evaluate Effectiveness of Investigational Device in the Assistance of Detection and Diagnosis of Breast Cancer
Role: lead
All 8 trials loaded